Contract biopharma plant opens in Finland

Related tags Good manufacturing practice Chemical engineering Water

In an unusual move, Finnish science park Medipolis has set up a new
Good Manufacturing Practice (GMP) pilot plant to take advantage of
the growing demand for biopharmaceutical production capacity.

In an unusual move, Finnish science park Medipolis has set up a new Good Manufacturing Practice (GMP) pilot plant to take advantage of the growing demand for biopharmaceutical production capacity.

The plant, operated by a company called Medipolis GMP, is designed to produce drugs, medical devices or diagnostics aids in pilot quantities for clinical trials, and has already been validated by Finland's regulatory agency (the NAM).

While a somewhat novel move for a science park, the new plant draws on the experience Medipolis has gained with a similar project, the operation of a chemical synthesis pilot plant, which was completed in 1998. This offers manufacturing of gram to kilogram quantities of active drug substances, as well as process development, and two years after being set up was converted into an independent company called Pharmatory.

Medipolis GMP provides both microbial (10-500 litres) and cell culture (10-100 litres) production, as well as downstream processing and a full cleanroom suite.

The new company's managing director, Sirkka Aho, said that Medipolis GMP​ is interested in forging partnerships with US biopharmaceutical players.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...